» Articles » PMID: 39916450

Medical Management of Adult Moyamoya Disease: A Review and Relevant Cases With Ischemic Events

Overview
Journal J Stroke
Date 2025 Feb 7
PMID 39916450
Authors
Affiliations
Soon will be listed here.
Abstract

Moyamoya disease (MMD) is a rare and progressive cerebrovascular disorder characterized by stenosis or occlusion of the internal carotid arteries resulting in the development of fragile collateral vessels at the base of the brain. Surgical revascularization is the primary treatment option for preventing ischemic and hemorrhagic events; however, the role of medical management has become increasingly recognized, particularly in cases involving asymptomatic patients or those at a high risk for surgical complications. In this review, we aimed to investigate the current guidelines and evidence supporting various medical management strategies for MMD, including the importance of controlling risk factors and judicious use of antithrombotic therapy. Given the considerable variability in patient presentation, such as age of onset, symptomatology, and comorbid conditions, it is crucial to adopt tailored therapeutic approaches that address each patient's unique characteristics. The existing literature on medical management is limited. However, individualized strategies may effectively mitigate the risk of ischemic events and improve the overall patient outcomes. Further research is essential to develop comprehensive and standardized treatment protocols for medical management of adult patients with MMD. In addition, ongoing trials and efforts to develop disease-modifying agents are discussed.

References
1.
Xu J, Zhang Q, Rajah G, Zhao W, Wu F, Ding Y . Daily Remote Ischemic Conditioning Can Improve Cerebral Perfusion and Slow Arterial Progression of Adult Moyamoya Disease-A Randomized Controlled Study. Front Neurol. 2022; 12:811854. PMC: 8850829. DOI: 10.3389/fneur.2021.811854. View

2.
Oki K, Katsumata M, Izawa Y, Takahashi S, Suzuki N, Houkin K . Trends of Antiplatelet Therapy for the Management of Moyamoya Disease in Japan: Results of a Nationwide Survey. J Stroke Cerebrovasc Dis. 2018; 27(12):3605-3612. DOI: 10.1016/j.jstrokecerebrovasdis.2018.08.030. View

3.
Lee W, Jeong S, Han K, Lee S, Ryu Y, Sohn C . Impact of Endothelial Shear Stress on the Bilateral Progression of Unilateral Moyamoya Disease. Stroke. 2019; 51(3):775-783. DOI: 10.1161/STROKEAHA.119.028117. View

4.
Bang O, Chung J, Cha J, Lee M, Yeon J, Ki C . A Polymorphism in RNF213 Is a Susceptibility Gene for Intracranial Atherosclerosis. PLoS One. 2016; 11(6):e0156607. PMC: 4890790. DOI: 10.1371/journal.pone.0156607. View

5.
Fujimura M, Funaki T, Houkin K, Takahashi J, Kuroda S, Tomata Y . Intrinsic development of choroidal and thalamic collaterals in hemorrhagic-onset moyamoya disease: case-control study of the Japan Adult Moyamoya Trial. J Neurosurg. 2018; 130(5):1453-1459. DOI: 10.3171/2017.11.JNS171990. View